Mural Oncology spins out from Alkermes with $275M and a lead immunotherapy program
Mural Oncology is spinning out of Alkermes with $275 million and a lead immunotherapy candidate already in two studies in mucosal melanoma and ovarian cancer.
On top of the funding, Alkermes is also distributing Mural stock to its shareholders — one Mural share for every 10 Alkermes shares they own.
The company will start trading on the Nasdaq on Nov. 16 under $MURA. Its lead drug, an interleukin-2 (IL-2) cytokine dubbed nemvaleukin alfa, is already in two registrational studies in mucosal melanoma as a monotherapy and another for platinum-resistant ovarian cancer in combination with pembrolizumab (Keytruda). Topline data are expected for both in the first quarter of 2025.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.